ArticleJournal of neuro-oncology2020
Molecular characteristics and clinical features of multifocal glioblastoma.
Article in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- Molecular features of intratumoral hemorrhage in glioblastoma isocitrate dehydrogenase-wildtype.Journal of neuro-oncology · 2026Article
- Role of Bevacizumab in Multiple Glioblastomas: A Retrospective Single-Center Analysis.Neurosciences (Riyadh, Saudi Arabia) · 2026Article
- Cystic glioblastoma IDH-wildtype: genetic alterations and outcomes.Journal of neuro-oncology · 2025Article
- A Radiologist's Guide to IDH-Wildtype Glioblastoma for Efficient Communication With Clinicians: Part I-Essential Information on Preoperative and Immediate Postoperative Imaging.Korean journal of radiology · 2025Review
- Discontiguous recurrences of IDH-wildtype glioblastoma share a common origin with the initial tumor and are frequently hypermutated.Acta neuropathologica communications · 2025Article
- Different risk factors for multiple and unifocal gliomas: a comparative study of radiological, pathological and clinical characteristics.Frontiers in oncology · 2025Article
- Assessing the predictability of isocitrate dehydrogenase mutational status in glioma patients using imaging features.Surgical neurology international · 2025Article
- Multimodal treatment of glioblastoma with multiple lesions - a multi-center retrospective analysis.Journal of neuro-oncology · 2024Article
- Molecular GBM versus Histopathological GBM: Radiology-Pathology-Genetic Correlation and the New WHO 2021 Definition of Glioblastoma.AJNR. American journal of neuroradiology · 2024Review
- Patterns of care and survival in patients with multifocal glioblastoma: A Danish cohort study.Neuro-oncology practice · 2024Article
- Imaging predictors of 4q12 amplified and RB1 mutated glioblastoma IDH-wildtype.Journal of neuro-oncology · 2024Article
- General Clinico-Pathological Characteristics in Glioblastomas in Correlation with p53 and Ki67.Medicina (Kaunas, Lithuania) · 2023Article
- From Theory to Practice: Implementing the WHO 2021 Classification of Adult Diffuse Gliomas in Neuropathology Diagnosis.Brain sciences · 2023Review
- A Head-to-Head Comparison ofJournal of clinical medicine · 2022Article
- Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review.Current oncology (Toronto, Ont.) · 2022Review
- Gene and protein expression profiles of olfactory ensheathing cells from olfactory bulbNeural regeneration research · 2022Article
- Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma.Journal of neuro-oncology · 2022Article
- Case report: tumor-treating fields prolongs IDH-mutant anaplastic astrocytoma progression-free survival and pathological evolution to glioblastoma.Annals of translational medicine · 2021Article
- PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma.Journal of neuro-oncology · 2021Article
- On the Prognosis of Multifocal Glioblastoma: An Evaluation Incorporating Volumetric MRI.Current oncology (Toronto, Ont.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlioblastomas (GBMs) usually occur as a solitary lesion; however, about 0.5-35% present with multiple lesions (M-GBM). The genetic landscape of GBMs have been thoroughly investigated; nevertheless, differences between M-GBM and single-foci GBM (S-GBM) remains unclear. The present study aimed to determine differences in clinical and molecular characteristics between M-GBM and S-GBM.
methodsA retrospective review of multifocal/multicentric infiltrative gliomas (M-IG) from our institutional database was performed. Demographics, clinical, radiological, and genetic features were obtained and compared between M-GBM IDH-wild type (IDH-WT) vs 193 S-GBM IDH-WT. Mutations were examined by a targeted next-generation sequencing assay interrogating 315 genes.
results33M-IG were identified from which 94% were diagnosed as M-GBM IDH-WT, the remaining 6% were diagnosed as astrocytomas IDH-mutant. M-GBM and S-GBM comparison revealed that EGFR alterations were more frequent in M-GBM (65% vs 42% p = 0.019). Furthermore, concomitant EGFR/PTEN alterations were more common in M-GBM vs. S-GBM (36% vs 19%) as well as compared to TCGA (21%). No statistically significant differences in overall survival were observed between M-GBM and S-GBM; however, within the M-GBM cohort, patients harboring KDR alterations had a worse survival (KDR-altered 6.7 vs KDR-WT 16.6 months, p = 0.038).
conclusionsThe results of the present study demonstrate that M-GBM genetically resembles S-GBM, however, M-GBM harbor higher frequency of EGFR alterations and co-occurrence of EGFR/PTEN alterations, which may account for their highly malignant and invasive phenotype. Further study of genetic alterations including differences between multifocal and multicentric GBMs are warranted, which may identify potential targets for this aggressive tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.